Results for this period
Full year1 April 2025–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Growth in revenue and profit was driven by pharmaceutical marketing support and digital transformation support for medical institutions, relatively high-margin projects, recruitment and job placement services, hospice and home-visit nursing services, new CS set contracts, and organic growth and acquisition contributions overseas. Acquisitions, including 株式会社イーウェル, also contributed, while U.S. policy changes and additional impairment losses had an adverse impact.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥351,363 million (YoY +23.3%) |
| Operating profit | ¥73,547 million (YoY +16.8%) |
| Ordinary income | ¥76,276 million (YoY +17.7%) |
| Profit attributable to owners of the parent | ¥49,100 million (YoY +21.3%) |
| Net income per share | ¥72.53 |
| Operating Margin | 20.9% |
| Equity ratio | End of the current fiscal period 64.0% / End of previous period 65.1% |
| Total assets | ¥637,396 million |
| Net assets | ¥446,648 million |
| Cash flows from operating activities | ¥70,262 million |
| Cash flows from investing activities | ¥-15,890 million |
| Cash flows from financing activities | ¥-35,471 million |
| Cash and cash equivalents at end of period | ¥156,177 million |
| Full-year earnings forecast | Net Sales ¥400,000 million (YoY +13.8%) / Operating profit ¥80,000 million (YoY +8.8%) / Ordinary income ¥81,000 million (YoY +6.2%) / Net income ¥56,000 million (YoY +3.6%) / Profit for the period attributable to owners of the parent ¥53,000 million (YoY +7.9%) |
| Annual Dividend Forecast | ¥21 → To be determined（To be determined） |
| Payout ratio | 30.3% |
| Segment revenue | Medical Platform ¥107,830 million (YoY +17.8%), Evidence Solutions ¥24,521 million (YoY +1.1%), Career Solutions ¥22,799 million (YoY +9.0%), Site Solutions ¥54,353 million (YoY +15.5%), Patient Solutions ¥56,877 million (YoY +159.5%), Overseas expansion ¥86,921 million (YoY +7.9%) |
| Segment profit | Medical Platform ¥35,918 million (YoY +5.3%), Evidence Solutions ¥5,120 million (YoY +17.8%), Career Solutions ¥5,925 million (YoY +4.8%), Site Solutions ¥5,766 million (YoY +6.3%), Patient Solutions ¥2,686 million (YoY +226.0%), Overseas expansion ¥14,898 million (YoY +1.0%) |
| Depreciation and amortization | ¥17,229 million |
| Impairment loss | ¥6,677 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 株式会社イーウェル / Excluded Number of companies 0 / Company name Not disclosed / Notes The cover page states that there were no significant changes to the scope of consolidation during the period. The main body states that 株式会社イーウェル became a subsidiary in April 2025 and was consolidated from that month. |
| Material subsequent events | At a meeting held on 1 May 2026, the Board of Directors resolved to repurchase treasury shares. The repurchase will cover up to 20 million common shares, with a total purchase price of up to ¥20 billion, during the period from 2 May 2026 to 30 April 2027. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 679,120,300 |
| Treasury Shares at Period-End | 11,695,137 |
| Factors Behind Changes in Business Performance | Growth in revenue and profit was driven by pharmaceutical marketing support and digital transformation support for medical institutions, relatively high-margin projects, recruitment and job placement services, hospice and home-visit nursing services, new CS set contracts, and organic growth and acquisition contributions overseas. Acquisitions, including 株式会社イーウェル, also contributed, while U.S. policy changes and additional impairment losses had an adverse impact. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Results were supported by steady performance in pharmaceutical marketing support, digital transformation support for medical institutions, recruitment and job placement services, hospice and home-visit nursing services, and new CS set contracts, as well as contributions from the acquisitions and the conversion into subsidiaries of Ewell, Noah Concert and Elan. Overseas operations benefited from organic growth and acquisitions, while the Company also expects effects from U.S. policy changes, impairment losses and the absence of gains on real estate sales.